Posted in Antibodies, Assay Kits, Biology Cells, cDNA, Clia Kits, Culture Cells, Devices, DNA, DNA Templates, DNA Testing, Elisa Kits, Enzymes, Equipments, Exosomes, Gels, Isotypes, Medium & Serums, NATtrol, Panel, Particles, PCR, Pcr Kits, Peptides, Reagents, Recombinant Proteins, Ria Kits, RNA, Test Kits, Vector & Virus, Western Blot
Top VHL Recombinant Protein For Human
Von Hippel-Lindau (VHL) Protein Antagonist VH298 Improves Wound Therapeutic in Streptozotocin-Induced Hyperglycaemic Rats by Activating Hypoxia-Inducible Issue- (HIF-) 1 Signalling.
The aim of the current analysis is to analyze the results of the VHL protein antagonist, VH298, on purposeful actions of fibroblasts and vascular endothelial cells and the results on the wound therapeutic course of in a streptozotocin-induced hyperglycaemic rat mannequin.
Strategies
HIF-1α and hydroxy-HIF-1α protein ranges in VH298-treated rat fibroblasts (rFb) had been measured by immunoblotting, rFb proliferation was detected by the CCK-Eight assay, and mRNA ranges of associated genes had been measured by quantitative RT-PCR. In vitro wound therapeutic was simulated by the scratch take a look at; angiogenesis was measured by the human umbilical vein endothelial cell (hUVEC) tube formation assay. VH298 or PBS was regionally injected into wounds in rat fashions with streptozotocbd tissues had been harvested, and haematoxylin-eosin (HE) and Masson trichrome staining and immunohistochemical processes had been carried out.
Human Von Hippel Lindau Tumor Suppressor (vHL) ELISA Equipment
Outcomes
HIF-1α and hydroxy-HIF-1α ranges elevated in VH298-treated rFb, in a time- and dose-dependent method. Thirty micromolar VH298 may considerably enhance cell proliferation, angiogenesis, and gene expression of sort I collagen-αα
Conclusions
Taken collectively, VH298 activated the HIF-1 signalling pathway by stabilizing each HIF-1α and hydroxy-HIF-1α. VH298 enhanced rFb capabilities, promoted hUVEC angiogenesis, and accelerated wound therapeutic within the rat mannequin mimicking diabetes mellitus.
Rat Von Hippel Lindau Tumor Suppressor (vHL) ELISA Equipment

Human Von Hippel Lindau Tumor Suppressor (vHL) ELISA Kit |
RD-vHL-Hu-48Tests |
Reddot Biotech |
48 Tests |
EUR 668.4 |
Human Von Hippel Lindau Tumor Suppressor (vHL) ELISA Kit |
RD-vHL-Hu-96Tests |
Reddot Biotech |
96 Tests |
EUR 930 |
Rat Von Hippel Lindau Tumor Suppressor (vHL) ELISA Kit |
RD-vHL-Ra-48Tests |
Reddot Biotech |
48 Tests |
EUR 668.4 |
Rat Von Hippel Lindau Tumor Suppressor (vHL) ELISA Kit |
RD-vHL-Ra-96Tests |
Reddot Biotech |
96 Tests |
EUR 930 |
Human Von Hippel Lindau Tumor Suppressor (vHL) ELISA Kit |
RDR-vHL-Hu-48Tests |
Reddot Biotech |
48 Tests |
EUR 699.6 |
Human Von Hippel Lindau Tumor Suppressor (vHL) ELISA Kit |
RDR-vHL-Hu-96Tests |
Reddot Biotech |
96 Tests |
EUR 973.2 |
Rat Von Hippel Lindau Tumor Suppressor (vHL) ELISA Kit |
RDR-vHL-Ra-48Tests |
Reddot Biotech |
48 Tests |
EUR 699.6 |
Rat Von Hippel Lindau Tumor Suppressor (vHL) ELISA Kit |
RDR-vHL-Ra-96Tests |
Reddot Biotech |
96 Tests |
EUR 973.2 |
VHL Antibody |
1-CSB-PA071125 |
Cusabio |
|
|
|
Description: A polyclonal antibody against VHL. Recognizes VHL from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:2000-1:5000, WB:1:500-1:2000, IHC:1:25-1:100 |
VHL Antibody |
1-CSB-PA060067 |
Cusabio |
|
|
|
Description: A polyclonal antibody against VHL. Recognizes VHL from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC:1/100-1/300.ELISA:1/40000 |
VHL Antibody |
1-CSB-PA991849 |
Cusabio |
|
|
|
Description: A polyclonal antibody against VHL. Recognizes VHL from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:10000, IHC:1:50-1:200 |
VHL Antibody |
1-CSB-PA876839 |
Cusabio |
|
|
|
Description: A polyclonal antibody against VHL. Recognizes VHL from Human. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC-p:1:50-300, ELISA:1:10000-20000 |
VHL Antibody |
CSB-PA025852KA01HU-100ul |
Cusabio |
100ul |
EUR 466.8 |
|
Description: A polyclonal antibody against VHL. Recognizes VHL from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;WB:1:500-1:2000, IHC:1:50-1:200 |
VHL antibody |
70R-34605 |
Fitzgerald |
100 ug |
EUR 392.4 |
Description: Purified Rabbit polyclonal VHL antibody |
VHL antibody |
70R-9757 |
Fitzgerald |
50 ug |
EUR 560.4 |
Description: Affinity purified rabbit polyclonal VHL antibody |
VHL Antibody |
32075-100ul |
SAB |
100ul |
EUR 302.4 |
VHL antibody |
10R-1029 |
Fitzgerald |
100 ul |
EUR 379.2 |
Description: Mouse monoclonal VHL antibody |
VHL Antibody |
CSB-PA025852KA01HU- |
Cusabio |
each |
EUR 402 |
|
Description: A polyclonal antibody against VHL. Recognizes VHL from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;WB:1:500-1:2000, IHC:1:50-1:200 |
VHL Conjugated Antibody |
C32075 |
SAB |
100ul |
EUR 476.4 |
VHL Polyclonal Antibody |
ES7499-100ul |
ELK Biotech |
100ul |
EUR 334.8 |
Description: A Rabbit Polyclonal antibody against VHL from Human/Mouse/Rat. This antibody is tested and validated for IHC, WB, ELISA |
VHL Polyclonal Antibody |
ES7499-50ul |
ELK Biotech |
50ul |
EUR 248.4 |
Description: A Rabbit Polyclonal antibody against VHL from Human/Mouse/Rat. This antibody is tested and validated for IHC, WB, ELISA |
VHL Polyclonal Antibody |
ES8746-100ul |
ELK Biotech |
100ul |
EUR 334.8 |
Description: A Rabbit Polyclonal antibody against VHL from Human. This antibody is tested and validated for IHC, WB, ELISA |
VHL Polyclonal Antibody |
ES8746-50ul |
ELK Biotech |
50ul |
EUR 248.4 |
Description: A Rabbit Polyclonal antibody against VHL from Human. This antibody is tested and validated for IHC, WB, ELISA |
VHL Polyclonal Antibody |
46866-100ul |
SAB |
100ul |
EUR 302.4 |
VHL Polyclonal Antibody |
46866-50ul |
SAB |
50ul |
EUR 224.4 |
Human VHL Antibody |
32825-05111 |
AssayPro |
150 ug |
EUR 313.2 |
VHL Polyclonal Antibody |
ABP56500-003ml |
Abbkine |
0.03ml |
EUR 189.6 |
|
Description: A polyclonal antibody for detection of VHL from Human, Mouse, Rat. This VHL antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human VHL around the non-phosphorylation site of S68 |
VHL Polyclonal Antibody |
ABP56500-01ml |
Abbkine |
0.1ml |
EUR 346.8 |
|
Description: A polyclonal antibody for detection of VHL from Human, Mouse, Rat. This VHL antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human VHL around the non-phosphorylation site of S68 |
VHL Polyclonal Antibody |
ABP56500-02ml |
Abbkine |
0.2ml |
EUR 496.8 |
|
Description: A polyclonal antibody for detection of VHL from Human, Mouse, Rat. This VHL antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human VHL around the non-phosphorylation site of S68 |
VHL Polyclonal Antibody |
ABP60891-003ml |
Abbkine |
0.03ml |
EUR 189.6 |
|
Description: A polyclonal antibody for detection of VHL from Human. This VHL antibody is for IHC-P, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human VHL protein at amino acid sequence of 1-50 |
VHL Polyclonal Antibody |
ABP60891-01ml |
Abbkine |
0.1ml |
EUR 346.8 |
|
Description: A polyclonal antibody for detection of VHL from Human. This VHL antibody is for IHC-P, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human VHL protein at amino acid sequence of 1-50 |
VHL Polyclonal Antibody |
ABP60891-02ml |
Abbkine |
0.2ml |
EUR 496.8 |
|
Description: A polyclonal antibody for detection of VHL from Human. This VHL antibody is for IHC-P, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human VHL protein at amino acid sequence of 1-50 |
VHL (pS68) Antibody |
abx219320-100ug |
Abbexa |
100 ug |
EUR 526.8 |
|
anti- VHL antibody |
FNab09402 |
FN Test |
100µg |
EUR 658.5 |
|
Description: Antibody raised against VHL |
anti- VHL antibody |
FNab10175 |
FN Test |
100µg |
EUR 606.3 |
|
Description: Antibody raised against VHL |
Anti-VHL antibody |
STJ113440 |
St John's Laboratory |
50 µl |
EUR 332.4 |
Description: Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed. |
Anti-VHL antibody |
STJ113742 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed. |
VHL Dependent Expression of REDD1 and PDK3 Proteins in Clear-cell Renal Cell Carcinoma.
- Sporadic clear-cell renal cell carcinoma (ccRCC) is related with mutations within the VHL gene, upregulated mammalian goal of rapamycin (mTOR) exercise and glycolytic metabolism. Right here, we analyze the impact of VHL mutational standing on the expression stage of mTOR, eIF4E-BP1, AMPK, REDD1, and PDK3 proteins.
pGF-AP1-mCMV-EF1-Puro (293 secure cell line)
- Complete proteins had been remoted from 21 tumorous samples with biallelic inactivation, 10 with monoallelic inactivation and 6 tumors with a wild-type VHL (wtVHL) gene obtained from sufferers who underwent complete nephrectomy. The expressions of goal proteins had been assessed utilizing Western blot.Expressions of mTOR, eIF4EBP1 and AMPOkay had been VHL impartial.
- Tumors with monoallelic inactivation of VHL underexpressed REDD1 compared to wtVHL tumors (P = 0.042), tumors with biallelic VHL inactivation (P < 0.005) and management tissue (P = 0.004). Moreover, REDD1 expression was larger in tumors with VHL biallelic inactivation than in management tissue (P = 0.008). Solely in wt tumor samples PDK3 was overexpressed compared to tumors with biallelic inactivation of VHL gene (P = 0.012) and controls (P = 0.016). In wtVHL ccRCC, multivariate linear regression evaluation revealed that 97.4% of variability in PDK3 expression might be defined by variations in AMPK quantity.Expressions of mTOR, eIF4EBP1 and AMPK had been VHL impartial.
- Now we have proven for the primary time VHL dependent expression of PDK3 and we offer extra proof that VHL mutational standing impacts REDD1 expression in sporadic ccRCC.
Gene Knock-Out HR Concentrating on Vector w/Single Choice Marker (Blasticidin) and Destructive Choice (TK) Towards Random Integration
-
VHL sufferers (n = 339) had been recruited and grouped primarily based on mutation sorts: HIF-α binding web site missense (HM) mutations, non-HIF-α binding web site missense (nHM) mutations, and truncating (TR) mutations. Age-related dangers of VHL-associated tumors and affected person survival had been in contrast.
-
Missense mutations conferred an elevated danger of pheochromocytoma (HR = 1.854, p = 0.047) in contrast with truncating mutations. The danger of pheochromocytoma was decrease within the HM group than within the nHM group (HR = 0.298, p = 0.003) however was related between HM and TR teams (HR = 0.901, p = 0.810).
Human Von Hippel Lindau Tumor Suppressor (vHL) ELISA Kit |
RDR-vHL-Hu-48Tests |
Reddot Biotech |
48 Tests |
EUR 699.6 |
Human Von Hippel Lindau Tumor Suppressor (vHL) ELISA Kit |
RDR-vHL-Hu-96Tests |
Reddot Biotech |
96 Tests |
EUR 973.2 |
Gene Knock-Out HR Targeting Vector [MCS1-EF1?-RFP-T2A-Puro-pA-MCS2] |
HR110PA-1 |
SBI |
10 ug |
EUR 1227.6 |
|
Gene Knock-Out HR Targeting Vector [MCS1-EF1a-GFP-T2A-Puro-pA-MCS2] |
HR410PA-1 |
SBI |
10 ug |
EUR 1227.6 |
|
Gene Knock-Out HR Targeting Vector [MCS1-EF1a-RFP-T2A-Hygro-pA-MCS2] |
HR510PA-1 |
SBI |
10 ug |
EUR 1227.6 |
|
TARGATT? Knock-in iPSC Generation (Master Cell Line) |
AST-1100 |
Applied StemCell |
1 vial of 1X10^6 cells |
Ask for price |
Description: 6 month |
Rat Von Hippel Lindau Tumor Suppressor (vHL) ELISA Kit |
DLR-vHL-Ra-48T |
DL Develop |
48T |
EUR 658.8 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Rat Von Hippel Lindau Tumor Suppressor (vHL) in samples from tissue homogenates or other biological fluids. |
Rat Von Hippel Lindau Tumor Suppressor (vHL) ELISA Kit |
DLR-vHL-Ra-96T |
DL Develop |
96T |
EUR 861.6 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Rat Von Hippel Lindau Tumor Suppressor (vHL) in samples from tissue homogenates or other biological fluids. |
Rat Von Hippel Lindau Tumor Suppressor (vHL) ELISA Kit |
RD-vHL-Ra-48Tests |
Reddot Biotech |
48 Tests |
EUR 668.4 |
Rat Von Hippel Lindau Tumor Suppressor (vHL) ELISA Kit |
RD-vHL-Ra-96Tests |
Reddot Biotech |
96 Tests |
EUR 930 |
Rat Von Hippel Lindau Tumor Suppressor (vHL) ELISA Kit |
RDR-vHL-Ra-48Tests |
Reddot Biotech |
48 Tests |
EUR 699.6 |
Rat Von Hippel Lindau Tumor Suppressor (vHL) ELISA Kit |
RDR-vHL-Ra-96Tests |
Reddot Biotech |
96 Tests |
EUR 973.2 |
TARGATT? Knock-in Mouse Cell Line Generation Kit (Master Cell Line) |
AST-7001 |
Applied StemCell |
1 Kit |
Ask for price |
Description: 6 month |
TARGATT? Knock-in CHO Generation Kit (Master Cell Line) |
AST-1200 |
Applied StemCell |
1 Kit |
Ask for price |
Description: 12 month |
TARGATT? Knock-in HEK293 Generation Kit (Master Cell Line) |
AST-1300 |
Applied StemCell |
1 Kit |
Ask for price |
Description: 12 month |
CFTR - HEK 293 Cell Line |
60506 |
BPS Bioscience |
2 vials |
EUR 7500 |
Description: The CFTR HEK293 Cell Line expresses full length, wild-type human cystic fibrosis transmembrane conductance regulator (CFTR) protein (Genbank #P13569, NP_000483.3), with a C-terminal Streptavidin-Binding Peptide (SBP) tag.Expression must be induced ≥24 hours prior to an experiment using 1 µg/ml Doxycycline and 3 mM Na-butyrate. The inducible expression of CFTR was confirmed by Western blotting and flow cytometry. |
VHL 3'UTR GFP Stable Cell Line |
TU078117 |
ABM |
1.0 ml |
EUR 1825.2 |
Vhl 3'UTR GFP Stable Cell Line |
TU273038 |
ABM |
1.0 ml |
Ask for price |
Vhl 3'UTR GFP Stable Cell Line |
TU171762 |
ABM |
1.0 ml |
Ask for price |
Vhl 3'UTR Luciferase Stable Cell Line |
TU223038 |
ABM |
1.0 ml |
Ask for price |
Vhl 3'UTR Luciferase Stable Cell Line |
TU121762 |
ABM |
1.0 ml |
Ask for price |
VHL 3'UTR Luciferase Stable Cell Line |
TU028117 |
ABM |
1.0 ml |
EUR 1825.2 |
Basic HR Targeting Vector [MCS1-LoxP-MCS2-MCS3-pA-LoxP-MCS4] for Gene Knock-In/Out |
HR100PA-1 |
SBI |
10 ug |
EUR 1125.6 |
|
Human VHL Antibody |
32825-05111 |
AssayPro |
150 ug |
EUR 313.2 |
Recombinant human VHL |
P2120 |
FN Test |
100ug |
Ask for price |
|
Description: Recombinant protein for human VHL |
VHL sgRNA CRISPR Lentivector set (Human) |
K2611301 |
ABM |
3 x 1.0 ug |
EUR 406.8 |
VHL antibody |
70R-34605 |
Fitzgerald |
100 ug |
EUR 392.4 |
Description: Purified Rabbit polyclonal VHL antibody |
VHL Antibody |
32075-100ul |
SAB |
100ul |
EUR 302.4 |
VHL Peptide |
45-170P |
ProSci |
0.1 mg |
EUR 405.6 |
Description: (IN) VHL Peptide |
VHL antibody |
10R-1029 |
Fitzgerald |
100 ul |
EUR 379.2 |
Description: Mouse monoclonal VHL antibody |
VHL antibody |
70R-9757 |
Fitzgerald |
50 ug |
EUR 560.4 |
Description: Affinity purified rabbit polyclonal VHL antibody |
VHL Antibody |
1-CSB-PA876839 |
Cusabio |
|
|
|
Description: A polyclonal antibody against VHL. Recognizes VHL from Human. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC-p:1:50-300, ELISA:1:10000-20000 |
VHL Antibody |
1-CSB-PA071125 |
Cusabio |
|
|
|
Description: A polyclonal antibody against VHL. Recognizes VHL from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:2000-1:5000, WB:1:500-1:2000, IHC:1:25-1:100 |
VHL Antibody |
1-CSB-PA060067 |
Cusabio |
|
|
|
Description: A polyclonal antibody against VHL. Recognizes VHL from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC:1/100-1/300.ELISA:1/40000 |
VHL Antibody |
1-CSB-PA991849 |
Cusabio |
|
|
|
Description: A polyclonal antibody against VHL. Recognizes VHL from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:10000, IHC:1:50-1:200 |
VHL Antibody |
CSB-PA025852KA01HU-100ul |
Cusabio |
100ul |
EUR 466.8 |
|
Description: A polyclonal antibody against VHL. Recognizes VHL from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;WB:1:500-1:2000, IHC:1:50-1:200 |
VHL Antibody |
CSB-PA025852KA01HU- |
Cusabio |
each |
EUR 402 |
|
Description: A polyclonal antibody against VHL. Recognizes VHL from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;WB:1:500-1:2000, IHC:1:50-1:200 |
Gene Knock-Out HR Targeting Vector w/Single Selection Marker (Blasticidin) and Negative Selection (TK) Against Random Integration |
HR720PA-1 |
SBI |
10 µg |
EUR 1374 |
|
Mouse pre-microRNA Expression Construct mir-293+294+295 |
MMIR-293-295-PA-CL |
SBI |
Bacterial Streak |
EUR 1161.6 |
|
293AAV Cell Line |
AAV-100 |
Cell Biolabs |
1 vial |
EUR 609.6 |
Description: The 293AAV Cell Line is derived from the parental 293 cells but selected for attributes that increase AAV production, including firmer attachment and larger surface area. |
293AD Cell Line |
AD-100 |
Cell Biolabs |
1 vial |
EUR 553.2 |
Description: The 293AD Cell Line is derived from the parental 293 cells but selected for attributes that increase adenovirus production, including firmer attachment and larger surface area. |
293LTV Cell Line |
LTV-100 |
Cell Biolabs |
1 vial |
EUR 609.6 |
Description: The 293LTV Cell Line is derived from the parental 293 cells but selected for attributes that increase lentiviral production, including fimrer attachment and larger surface area. |
293RTV Cell Line |
RV-100 |
Cell Biolabs |
1 vial |
EUR 609.6 |
Description: The 293RTV Cell Line is derived from the parental 293 cells but selected for attributes that increase retroviral production, including fimrer attachment and larger surface area. |
Human VHL shRNA Plasmid |
20-abx955082 |
Abbexa |
|
|
|
VHL Recombinant Protein (Human) |
RP034324 |
ABM |
100 ug |
Ask for price |
Gene Knock-Out HR Targeting Vector w/Dual Selection Markers (GFP+Puro) and Negative Selection (TK) Against Random Integration |
HR700PA-1 |
SBI |
10 µg |
EUR 1374 |
|
Gene Knock-Out HR Targeting Vector w/Dual Selection Markers (RFP+Hygro) and Negative Selection (TK) Against Random Integration |
HR710PA-1 |
SBI |
10 µg |
EUR 1374 |
|
VHL sgRNA CRISPR Lentivector (Human) (Target 1) |
K2611302 |
ABM |
1.0 ug DNA |
EUR 184.8 |
VHL sgRNA CRISPR Lentivector (Human) (Target 2) |
K2611303 |
ABM |
1.0 ug DNA |
EUR 184.8 |
VHL sgRNA CRISPR Lentivector (Human) (Target 3) |
K2611304 |
ABM |
1.0 ug DNA |
EUR 184.8 |
T47D/GFP Cell Line |
AKR-208 |
Cell Biolabs |
1 vial |
EUR 686.4 |
Description: T47D/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line. |
A549/GFP Cell Line |
AKR-209 |
Cell Biolabs |
1 vial |
EUR 686.4 |
Description: A549/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line. |
HeLa/GFP Cell Line |
AKR-213 |
Cell Biolabs |
1 vial |
EUR 686.4 |
Description: HeLa/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line. |
NIH3T3/GFP Cell Line |
AKR-214 |
Cell Biolabs |
1 vial |
EUR 686.4 |
Description: NIH3T3/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line. |
NIH3T3/Cas9 Cell Line |
AKR-5104 |
Cell Biolabs |
1 vial |
EUR 686.4 |
TARGATT? Knock-in iPSC Genotyping Kit |
AST-1102 |
Applied StemCell |
1 Kit |
Ask for price |
Description: 12 month |
Microplate Swing-Out Centrifuge |
abx725026-1Unit |
Abbexa |
1 Unit |
EUR 1771.2 |
|
Clinical Swing-Out Centrifuge |
abx725027-1Unit |
Abbexa |
1 Unit |
EUR 1771.2 |
|
Gene Knock-Out HR Targeting Vector with TK selection [MCS1-LoxP-EF1?-GFP-T2A-Puro-P2A-hsvTK-pA-LoxP-MCS2] |
HR210PA-1 |
SBI |
10 ug |
EUR 1374 |
|
VHL Rabbit pAb |
A0377-100ul |
Abclonal |
100 ul |
EUR 369.6 |
VHL Rabbit pAb |
A0377-200ul |
Abclonal |
200 ul |
EUR 550.8 |
VHL Rabbit pAb |
A0377-20ul |
Abclonal |
20 ul |
EUR 219.6 |
VHL Rabbit pAb |
A0377-50ul |
Abclonal |
50 ul |
EUR 267.6 |
VHL Mouse mAb |
A11872-100ul |
Abclonal |
100 ul |
Ask for price |
VHL Mouse mAb |
A11872-200ul |
Abclonal |
200 ul |
Ask for price |
VHL Mouse mAb |
A11872-20ul |
Abclonal |
20 ul |
Ask for price |
VHL Mouse mAb |
A11872-50ul |
Abclonal |
50 ul |
EUR 318 |
VHL Rabbit pAb |
A11240-100ul |
Abclonal |
100 ul |
EUR 369.6 |
VHL Rabbit pAb |
A11240-200ul |
Abclonal |
200 ul |
EUR 550.8 |
VHL Rabbit pAb |
A11240-20ul |
Abclonal |
20 ul |
EUR 219.6 |
VHL Rabbit pAb |
A11240-50ul |
Abclonal |
50 ul |
EUR 267.6 |
VHL Polyclonal Antibody |
46866-100ul |
SAB |
100ul |
EUR 302.4 |
VHL Polyclonal Antibody |
46866-50ul |
SAB |
50ul |
EUR 224.4 |
-
Sufferers within the nHM group had the next danger of pheochromocytoma (HR = 3.447, p < 0.001) and decrease dangers of central nervous system hemangioblastoma (CHB) (HR = 0.700, p = 0.045), renal cell carcinoma (HR = 0.610, p = 0.024), and pancreatic tumor (HR = 0.382, p < 0.001) than these within the mixed HM and TR (HMTR) group.
-
Furthermore, nHM mutations had been independently related to better general survival (HR = 0.345, p = 0.005) and CHB-specific survival (HR = 0.129, p = 0.005) than HMTR mutations.
-
The modified genotype-phenotype correlation hyperlinks VHL gene mutation, substrate binding web site, and phenotypic range (penetrance and survival), and offers extra correct data for genetic counseling and pathogenesis research.